Breast Cancer Research and Treatment
Papers 10000
1 page of 1,000 pages (10k results)
#1Hiltrud Merzenich (University of Mainz)H-Index: 10
#2Dan Baaken (University of Mainz)H-Index: 2
Last. Maria Blettner (University of Mainz)H-Index: 69
view all 12 authors...
PURPOSE Radiotherapy (RT) was identified as a risk factor for long-term cardiac effects in breast cancer patients treated until the 1990s. However, modern techniques reduce radiation exposure of the heart, but some exposure remains unavoidable. In a retrospective cohort study, we investigated cardiac mortality and morbidity of breast cancer survivors treated with recent RT in Germany. METHODS A total of 11,982 breast cancer patients treated between 1998 and 2008 were included. A mortality follow...
#1A. Hernando-Calvo (Princess Margaret Cancer Centre)
#2David W. Cescon (Princess Margaret Cancer Centre)H-Index: 19
Last. Philippe L. Bedard (Princess Margaret Cancer Centre)H-Index: 53
view all 3 authors...
Immune-checkpoint inhibitors have profoundly changed the treatment landscape for many tumor types. Despite marked improvements in disease control for highly immunogenic cancers, the clinical impact of checkpoint inhibitors in breast cancers to date is limited. Breast cancer is a heterogeneous disease with different levels of PD-L1 expression and variable tumor microenvironment (TME) composition according to molecular subtype. With emerging evidence of the role of different factors involved in im...
#1Sho Shiino (University of Nottingham)H-Index: 3
#2Graham Ball (NTU: Nottingham Trent University)H-Index: 44
Last. Emad A. Rakha (University of Nottingham)H-Index: 75
view all 9 authors...
This meta-analysis aimed to investigate whether receptor (estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor 2 [HER2]) discordances between primary and recurrent breast cancers affect patients’ survival. Search terms contained ER, PR, and HER2 status details in both primary and recurrent tumors (local recurrence or distant metastasis) in addition to survival outcome data (overall survival [OS] or post-recurrence survival [PRS]). Loss of ER or PR in rec...
#1N. Bianco (IEO: European Institute of Oncology)H-Index: 3
#2Monica Milano (IEO: European Institute of Oncology)H-Index: 4
Last. Giuseppe Viale (IEO: European Institute of Oncology)H-Index: 134
view all 10 authors...
Metastatic triple negative breast cancer (mTNBC) is associated with poor prognosis and limited treatment options. It is known to be high immunogenic, with a high level of programmed cell death-ligand 1 (PD-L1) expression. PD-L1 expression in TNBC does not have a clear prognostic relevance. In this study, we aimed to assess survival outcomes according to PD-L1 expression in the real world. We retrospectively analyzed mTNBC patients treated with first-line chemotherapy at European Institute of Onc...
#1Andrés Vargas (UDP: Diego Portales University)
#2Katarzyna Holub (University of Barcelona)H-Index: 4
Last. Albert Biete (University of Barcelona)H-Index: 18
view all 3 authors...
We retrospectively reviewed the data from patients ≥ 70 years old treated between January 2012 and January 2017. Axillary staging was scarcely used in the therapeutic algorithm but arm lymphedema was significantly associated to axillar dissection (p=0.04) and regional nodal irradiation (p = 0.02). Aggressive management of axilla did not provide relevant information for deciding chemotherapy but added morbidity.
#1Utku Can Dölen (WashU: Washington University in St. Louis)H-Index: 7
#2Jody Law (WashU: Washington University in St. Louis)
Last. Terence M. Myckatyn (WashU: Washington University in St. Louis)H-Index: 30
view all 4 authors...
Breast cancer is diagnosed at a median age of 62 years in the USA. At the same time, mortality rates for breast cancer continue to decrease, falling by 40% from 1989 to 2016. In the coming decades, the number of elderly patients with breast cancer, potentially seeking reconstruction, is expected to increase. A retrospective chart review of 309 patients, aged 60 years or older, undergoing immediate or delayed breast reconstruction, was conducted. Patient characteristics, clinical information and ...
#1Naoko Takigami (Tohoku University)H-Index: 2
#2Shimpei Kuniyoshi (Tohoku University)H-Index: 1
Last. Ayako Kanai (Tohoku University)H-Index: 3
view all 14 authors...
#1Clément Morgat (University of Bordeaux)H-Index: 7
#2Véronique BrousteH-Index: 25
Last. Elif Hindié (University of Bordeaux)H-Index: 44
view all 6 authors...
Neurotensin receptor-1 (NTS1) is increasingly recognized as a potential target in diverse tumors including breast cancer, but factors associated with NTS1 expression have not been fully clarified. We studied NTS1 expression using the Tissue MicroArray (TMA) of primary breast tumors from Institut Bergonie. We also studied association between NTS1 expression and clinical, pathological, and biological parameters, as well as patient outcomes. Out of 1419 primary breast tumors, moderate to strong pos...
#1Osama Ibrahim Ibrahim Soliman (National University of Ireland, Galway)H-Index: 45
#2Aoife Lowery (National University of Ireland, Galway)H-Index: 20
view all 4 authors...
#1Gabrielle B. Rocque (UAB: University of Alabama at Birmingham)H-Index: 16
#2Nicole Caston (UAB: University of Alabama at Birmingham)
Last. Risha Gidwani (UCLA: University of California, Los Angeles)H-Index: 12
view all 7 authors...
The extent to which evidence-based treatments are applied to populations not well represented in early stage breast cancer (EBC) trials remains unknown. This study evaluated treatment intensity for patients traditionally well represented, underrepresented, and unrepresented in clinical trials. This retrospective cohort study used real-world data to evaluate the intensity (high or low) of EBC chemotherapy by patient characteristics (age, race and ethnicity, presence of comorbidity) denoting clini...
Top fields of study
Cancer research
Breast cancer